Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CFDA Accepts Ascentage's IND Filing for Lead Drug in Hepatitis B

publication date: Jan 9, 2018

Suzhou's Ascentage Pharma reported the CFDA has accepted its IND submission for APG-1387 as a treatment for hepatitis B. The novel molecule aims to restore apoptosis (programmed cell death) and eradicate hepatitis B rather than suppressing the virus. Ascentage is developing apoptosis-promoting drugs, mostly as treatments for cancer. APG-1387 would be the first inhibitor of apoptosis inhibitors (IAP) tested in hepatitis B. Ascentage is already conducting clinical trials of APG-1387 in cancer, one of its portfolio of six clinical stage IAP candidates. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here